Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
Status:
Withdrawn
Trial end date:
2019-11-12
Target enrollment:
Participant gender:
Summary
This clinical trial will assess the safety and early efficacy of the role of gedatolisib and
hydroxychloroquine in early-stage breast cancer patients with residual disease and evidence
of disseminated tumor cells (DTCs) on bone marrow aspirate after neoadjuvant chemotherapy
(NACT) and definitive surgery.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Collaborators:
Breast Cancer Research Foundation Hoosier Cancer Research Network Pfizer Translational Breast Cancer Research Consortium Translational Breast Cancer Research Consortium (TBCRC)